ALXO Q2 2020 Earnings — ALX Oncology Holdings Inc. Revenue & Financial Results | Market Cap Arena

ALXOALX Oncology Holdings Inc.

$113M

Q2 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$527,000-59.3% YoY

Gross Profit

$48,0009.1% margin

Operating Income

-$11M-2046.9% margin

Net Income

-$11M-2150.1% margin

EPS (Diluted)

$-0.33

QoQ Revenue Growth

-19.5%

Cash Flow

Operating Cash Flow

-$6M

Free Cash Flow

-$6M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$103M

Total Liabilities

$12M

Stockholders' Equity

$91M

Cash & Equivalents

$98M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$527,000	$1M	-59.3%
Gross Profit	$48,000	$118,000	-59.3%
Operating Income	-$11M	-$4M	-157.5%
Net Income	-$11M	-$4M	-170.0%